Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC

Abstract

Next-generation sequencing has provided information on actionable targets and biomarkers of response in oncology. In hepatocellular carcinoma (HCC), Wnt/CTNNB1 mutations characterize the immune-excluded class (cold tumors) and might represent the biomarkers predicting resistance to immune checkpoint inhibitors. Large-scale validation of these data is needed to customize immunotherapy in advanced HCC.

Document Details

Document Type
Pub Defense Publication
Publication Date
Apr 01, 2019
Source ID
10.1158/1078-0432.ccr-18-3778

Entities

People

  • Daniela Sia
  • Josep M. Llovet
  • Roser Pinyol

Organizations

  • Cancer Research UK
  • Catalan Institution for Research and Advanced Studies
  • European Institute of Innovation and Technology
  • Generalitat of Catalonia
  • Horizon 2020
  • Icahn School of Medicine at Mount Sinai
  • National Cancer Institute
  • National Institutes of Health
  • United States Department of Defense
  • University of Barcelona

Tags

Fields of Study

  • Biology

Readers

  • Oncology
  • Oncology and Biomarker-Based Cancer Detection.

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech